FUDANZHANGJIANG (688505.SH): Aminolevulinic Acid Hydrochloride Granules for Visualization in Bladder Cancer Surgery Receives Drug Marketing Application Acceptance Notice
FudanZhangjiang (688505.SH) announced that the company recently received the "Notice of Acceptance" issued upon approval by the National Medical Products Administration. The marketing application for the aminolevulinic acid hydrochloride granules developed by the company for adjunctive use in surgical resection of non-muscle-invasive bladder cancer has been accepted. If the drug is approved for marketing in the future, it will further enrich the company's product pipeline and enhance the company's overall competitiveness.
FUDANZHANGJIANG (688505.SH) announced that the company recently received the "Acceptance Notice" approved and issued by the National Medical Products Administration. The marketing application for the aminolevulinic acid hydrochloride granules developed by the company for adjuvant use in surgical resection of non-muscle-invasive bladder cancer has been accepted. If the drug is approved for marketing in the future, it will further enrich the company's product line and enhance the company's overall competitiveness.
Related Articles

MS CONCEPT (08447) announces interim results, with a net loss of HK$1.521 million.

Zijin Mining Group (02899) plans to repurchase RMB2 billion to RMB3 billion of its A-shares.

US Stock Market Move | NVIDIA Corporation (NVDA.US) rose 4%; institutions believe the stock price has already priced in the risk of leadership changes.
MS CONCEPT (08447) announces interim results, with a net loss of HK$1.521 million.

Zijin Mining Group (02899) plans to repurchase RMB2 billion to RMB3 billion of its A-shares.

US Stock Market Move | NVIDIA Corporation (NVDA.US) rose 4%; institutions believe the stock price has already priced in the risk of leadership changes.






